These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 1546744)

  • 21. Monoclonal immunoglobulin deposition disease: light chain and light and heavy chain deposition diseases and their relation to light chain amyloidosis. Clinical features, immunopathology, and molecular analysis.
    Buxbaum JN; Chuba JV; Hellman GC; Solomon A; Gallo GR
    Ann Intern Med; 1990 Mar; 112(6):455-64. PubMed ID: 2106817
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structural identity of Bence Jones and amyloid fibril proteins in a patient with plasma cell dyscrasia and amyloidosis.
    Terry WD; Page DL; Kimura S; Isobe T; Osserman EF; Glenner GG
    J Clin Invest; 1973 May; 52(5):1276-81. PubMed ID: 4700495
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Kinetic stability and sequence/structure studies of urine-derived Bence-Jones proteins from multiple myeloma and light chain amyloidosis patients.
    Blancas-Mejía LM; Martin EB; Williams A; Wall JS; Ramirez-Alvarado M
    Biophys Chem; 2017 Nov; 230():89-98. PubMed ID: 28916410
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Light chain renal amyloidosis with prominent giant cells.
    Troxell ML; Griffiths R; Schnadig I; Houghton DC
    Am J Kidney Dis; 2013 Dec; 62(6):1193-7. PubMed ID: 23891357
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A case of primary immunoglobulin light chain amyloidosis with a delayed appearance of Bence Jones protein in urine.
    Kurusu A; Yamada T; Yamaji K; Nishitani M; Tashiro K; Maeda K; Horikoshi S; Shirato I; Rinno H; Tomino Y
    Nephrology (Carlton); 2004 Jun; 9(3):122-5. PubMed ID: 15189172
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Complete amino acid sequence determinations demonstrate identity of the urinary Bence Jones protein (BJP-DIA) and the amyloid fibril protein (AL-DIA) in a case of AL-amyloidosis.
    Klafki HW; Kratzin HD; Pick AI; Eckart K; Karas M; Hilschmann N
    Biochemistry; 1992 Mar; 31(12):3265-72. PubMed ID: 1554711
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Imaging mass spectrometry analysis of renal amyloidosis biopsies reveals protein co-localization with amyloid deposits.
    Casadonte R; Kriegsmann M; Deininger SO; Amann K; Paape R; Belau E; Suckau D; Fuchser J; Beckmann J; Becker M; Kriegsmann J
    Anal Bioanal Chem; 2015 Jul; 407(18):5323-31. PubMed ID: 25935672
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Amyloid neuropathies. Histopathological study of peripheral nerve biopsy in 18 cases].
    Bouillot S; Vital A; Favereaux A; Ferrer X; Lagueny A; Vital C
    Ann Pathol; 2003 Apr; 23(2):114-20. PubMed ID: 12843966
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 2A4 binds soluble and insoluble light chain aggregates from AL amyloidosis patients and promotes clearance of amyloid deposits by phagocytosis
    Renz M; Torres R; Dolan PJ; Tam SJ; Tapia JR; Li L; Salmans JR; Barbour RM; Shughrue PJ; Nijjar T; Schenk D; Kinney GG; Zago W
    Amyloid; 2016 Sep; 23(3):168-177. PubMed ID: 27494229
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of single point mutations in a form of systemic amyloidosis.
    Bhavaraju M; Hansmann UH
    Protein Sci; 2015 Sep; 24(9):1451-62. PubMed ID: 26105812
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Co-deposition of amyloidogenic immunoglobulin light and heavy chains in localized pulmonary amyloidosis.
    Kaplan B; Martin BM; Boykov O; Gal R; Pras M; Shechtman I; Saute M; Kramer MR
    Virchows Arch; 2005 Oct; 447(4):756-61. PubMed ID: 16021505
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pathology and diagnosis of renal non-AL amyloidosis.
    Sethi S; Theis JD
    J Nephrol; 2018 Jun; 31(3):343-350. PubMed ID: 28828707
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Pulmonary amyloidosis and non-amyloid immunoglobulin deposits].
    Cordier JF
    Rev Mal Respir; 2008 Jun; 25(6):743-65. PubMed ID: 18772831
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Primary diffuse tracheobronchial amyloidosis in a dog.
    Labelle P; Roy ME; Mohr FC
    J Comp Pathol; 2004 Nov; 131(4):338-40. PubMed ID: 15511543
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunoglobulin light chain amyloidosis: 2018 Update on diagnosis, prognosis, and treatment.
    Gertz MA
    Am J Hematol; 2018 Sep; 93(9):1169-1180. PubMed ID: 30040145
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Systemic kappaAL amyloidosis associated with bovine leukocyte adhesion deficiency.
    Taniyama H; Yamamoto S; Sako T; Hirayama K; Higuchi H; Nagahata H
    Vet Pathol; 2000 Jan; 37(1):98-100. PubMed ID: 10643989
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pathogenic potential of human monoclonal immunoglobulin light chains: relationship of in vitro aggregation to in vivo organ deposition.
    Myatt EA; Westholm FA; Weiss DT; Solomon A; Schiffer M; Stevens FJ
    Proc Natl Acad Sci U S A; 1994 Apr; 91(8):3034-8. PubMed ID: 8159701
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fibrillary deposits: amyloids and tactoids.
    Looi LM
    Malays J Pathol; 1995 Jun; 17(1):1-10. PubMed ID: 8906998
    [TBL] [Abstract][Full Text] [Related]  

  • 39. AL amyloid imaging and therapy with a monoclonal antibody to a cryptic epitope on amyloid fibrils.
    Wall JS; Kennel SJ; Williams A; Richey T; Stuckey A; Huang Y; Macy S; Donnell R; Barbour R; Seubert P; Schenk D
    PLoS One; 2012; 7(12):e52686. PubMed ID: 23300743
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.